The most favorable outcomes, specifically regarding increased TIR, reduced TAR and TBR, and lower GRI were observed in study participants previously treated with insulin pumps, worse baseline glycemic control (HbA1c ≥ 7.0%), lower BMI, longer duration of diabetes (>15 years). The gene discussed is INS; the disease is diabetes mellitus.